Expertos Invitados





INHIBIDORES DE LA BOMBA DE PROTONES. ACTUALIZACION

(especial para SIIC © Derechos reservados)
La eficacia de los inhibidores de la bomba de protones es claramente superior a la de otras opciones terapéuticas.
cortisarem9.jpg Autor:
Rodolfo Corti
Columnista Experto de SIIC

Institución:
Unidad de Esófago y Estómago, Hospital de Gastroenterología B. Udaondo

Artículos publicados por Rodolfo Corti
Coautores
Rafael Améndola* Judith Doweck** Liliana Schenone** Amado Escobar* José Luis Ayoroa* Muhannad Sarem*** 
Médico Especialista en Gastroenterología, Unidad de Esófago y Estómago, Hospital de Gastroenterología B. Udaondo, Buenos Aires, Argentina*
Médica Especialista en Gastroenterología, Unidad de Esófago y Estómago, Hospital de Gastroenterología B. Udaondo, Buenos Aires, Argentina**
Investigador, Instituto Universitario de Ciencias de la Salud, Fundación H. Barceló, Buenos Aires, Argentina***
Recepción del artículo
23 de Marzo, 2006 		Aprobación
22 de Mayo, 2006
Primera edición
13 de Julio, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

INHIBIDORES DE LA BOMBA DE PROTONES. ACTUALIZACION

Resumen
Puesta al día sobre las drogas de mayor efectividad en la terapéutica de las enfermedades relacionadas con el ácido, se hace referencia a sus características farmacológicas y efectividad en el tratamiento de la úlcera gástrica, duodenal y enfermedad por reflujo gastroesofágico. Se hace referencia además a las nuevas estructuras químicas en investigación, como el tenatoprazol, los inhibidores de la bomba buffereados (omeprazol + bicarbonato de sodio) y los antagonistas de la bomba de ácido (soraprazan, revaprazan, AZD0865 y CS-526), hasta la actualidad sin uso clínico por su hepatotoxicidad.

Palabras clave
inhibidores de la bomba de protones, farmacología, aplicaciones clínicas


Artículo completo
(castellano)
Extensión:  +/-11.62 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Proton Pump Inhibitors: An Update

Abstract
We reviewed the most effective drugs used in acid-related disorders with emphasis on their pharmacological characteristics and usefulness in the treatment of gastric ulcers, duodenal ulcers and gastro-oesophageal reflux disease. Also, novel molecules and chemical structures that have not yet been used in clinic applications, like tenatoprazole, new immediate-release omeprazole (IR-OME) and acid pump antagonists (soraprazan, revaprazan, AZD0865 y el CS-526) are discussed in this review.

Key words
proton-pump inhibitors, pharmacology, clinical applications

Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Gastroenterología
Relacionadas: Atención Primaria, Farmacología, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 11.62 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Muhannad Sarem
Bibliografía del artículo
1. Sachs G, Berglindh T, Rabon E, Stewart HB, Barcellona ML, Wallmark B, Saccomani G. Aspects of parietal cell biology: cells and vesicles. Ann N Y Acad Sci 1980; 341:312-34.
2. Sachs G, Wallmark B. The gastric H+,K+-ATPase: the site of action of omeprazole. Scand J Gastroenterol Suppl 1989; 166:3-11.
3. Rabon E, Cuppoletti J, Malinowska D, Smolka A, Helander HF, Mendlein J, Sachs G. Proton secretion by the gastric parietal cell. J Exp Biol 1983; 106:119-33.
4. Steinmetz PR, Andersen OS. Electrogenic proton transport in epithelial membranes. J Membr Biol 1982; 65(3):155-74.
5. Saccomani G, Chang HH, Mihas AA, Crago S, Sachs G. An acid transporting enzyme in human gastric mucosa. J Clin Invest 1979; 64(2):627-35.
6. Gustin MC, Goodman DB. Isolation of brush-border membrane from the rabbit descending colon epithelium. Partial characterization of a unique K+-activated ATPase. J Biol Chem 1981; 256(20):10651-6.
7. Wingo CS, Smolka AJ. Function and structure of H-K-ATPase in the kidney. Am J Physiol 1995; 269(1 Pt 2):F1-16.
8. DuBose TD Jr, Gitomer J, Codina J. H+,K+-ATPase. Curr Opin Nephrol Hypertens 1999; 8(5):597-602.
9. Madsen KM, Tisher CC. Structure-function relationships in H+-secreting epithelia. Fed Proc1985; 44(11):2704-9.
10. Sachs G, Spenney JG, Rehm WS. Gastric secretion. Int Rev Physiol 1977; 12:127-71.
11. Bass P. Gastric antisecretory and antiulcer agents. Adv Drug Res 1974; 8:205-334.
12. Lee YH, Phillips E, Sause HW. Anti-gastrin activities of 2-phenyl-2-(2-pyridyl) thioacetamide (SC-15396) and structurally-related compounds in experimental animals. Arch Int Pharmacodyn Ther 1972; 195(2):402-10.
13. Ruwart MJ, Nezamis JE, Rush BD, Lancaster C, Davis JP, Nichols NM, Ochoa R. Timoprazole is a unique cytoprotective agent in the rat. Digestion. 1984; 30(1):33-40.
14. Tolman KG, Chandramouli J, Fang JC. Proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. Expert Opin Pharmacother 2000; 1(6):1171-94.
15. Wittmann T, Rosztoczy A, Feher A, Jarmay K, Olah T, Szendrenyi V, Kiss I. Drug therapy of gastroesophageal reflux (a prospective controlled clinical trial) Orv Hetil 1998; 139(18):1077-81.
16. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20(3):153-67.
17. Corti RE. Inhibidores de la bomba de protones. Avances en medicina Interna (II).Editorial Celcius, Buenos Aires, 1995.
18. Schepp W. Proton pump inhibitory therapy: then and now. Yale J Biol Med 1996; 69(2):175-86.
19. Clissold SP, Campoli-Richards DM. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs 1986; 32(1):15-47. Review. Erratum in: Drugs 1986; 32(5):preceding 383.
20. Adams MH, Ostrosky JD, Kirkwood CF. Therapeutic evaluation of omeprazole. Clin Pharm 1988; 7(10):725-45.
21. Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl 1989; 166:33-40; discussion 41-2.
22. Oosterhuis B, Jonkman JH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion 1989; 44 Suppl 1:9-17.
23. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000; 118(2 Suppl 1):S9-31.
24. Sachs G, Munson K, Hall K, Hersey SJ. Gastric H+,K(+)-ATPase as a therapeutic target in peptic ulcer disease. Dig Dis Sci 1990; 35(12):1537-44.
25. Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl 1989; 166:33-40; discussion 41-2.
26. Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990; 29(5):557-63.
27. Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44(2):225-50.
28. Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet 1998; 23(1):19-26.
29. Regardh CG, Andersson T, Lagerstrom PO, Lundborg P, Skanberg I. The pharmacokinetics of omeprazole in humans--a study of single intravenous and oral doses. Ther Drug Monit 1990; 12(2):163-72.
30. Andersson T, Cederberg C, Regardh CG, Skanberg I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. Eur J Clin Pharmacol 1990; 39(2):195-7.
31. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51(3):460-82.
32. Huber R, Hartmann M, Bliesath H, Luhmann R, Steinijans VW, Zech K. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34(1 Suppl):S7-16.
33. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62(10):1503-38.
34. Thitiphuree S, Talley NJ. Esomeprazole, a new proton pump inhibitor: pharmacological characteristics and clinical efficacy. Int J Clin Pract 2000; 54(8):537-41.
35. Miner P Jr, Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98(12):2616-20.
36. Wilder-Smith CH, Rohss K, Nilsson-Pieschl C, Junghard O, Nyman L. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003; 68(4):184-8.
37. Jungnickel PW. Pantoprazole: a new proton pump inhibitor. Clin Ther 2000; 22(11):1268-93.
38. Gremse DA. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses. Expert Opin Pharmacother 2001; 2(10):1663-70.
39. Der G. An overview of proton pump inhibitors. Gastroenterol Nurs 2003; 26(5):182-90.
40. Mears JM, Kaplan B. Proton pump inhibitors: new drugs and indications. Am Fam Physician 1996; 53(1):285-92.
41. Freston JW. Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy. Digestion 1992; 51 Suppl 1:102-14.
42. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56(23 Suppl 4):S11-7.
43. Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005; 22 Suppl 1:55-63.
44. Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol 2001; 116(5):716-20.
45. Mazzacca G, Sabbatini F. Inhibition of gastric acid secretion: advantages and risks in short and long-term treatment. Ital J Gastroenterol 1990; 22 Suppl 1:11-2.
46. Nelis GF, Engelage AH, Samson G. Does long-term inhibition of gastric acid secretion with omeprazole lead to small intestinal bacterial overgrowth? Neth J Med 1994; 45(3):93-100.
47. Garnett WR, Prescott J. Coprescribing proton pump inhibitors with other medications. Manag Care Interface 2000; 13(9):71-6, 79.
48. Flockhart DA, Desta Z, Mahal SK. Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions. Clin Pharmacokinet 2000; 39(4):295-309.
49. Classen M, Della Fave G: Management of acid-related diseases: focus on pantoprazole. Proceedings of the 1st International Symposium on Pantoprazole. Berlin, Germany, 1 May 1993. Aliment Pharmacol Ther 1994; 8 Suppl 1:1-70.
50. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996; 34(6):243-62.
51. Miehlke S, Madisch A, Kirsch C, Lindner F, Kuhlisch E, Laass M, Knoth H, Morgner A, Labenz J. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study. Aliment Pharmacol Ther 2005 15; 21(8):963-7.
52. Corti R, Améndola R, Menéndez G, Diwecj J, Schenone L, Soutric J, Caruso N. Acid-supressing capacity of omeprazole 20 mg tablets vs pantoprazole 20 and 40 mg tablets. A pilot study in volunteers Acta Gastroenterol Latinoam 2003; 33(4):199-203.
53. Mulder CJ, Dekker W, Gerretsen M. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group. Eur J Gastroenterol Hepatol 1996; 8(11):1101-6.
54. Freston JW, Jackson RL, Huang B, Ballard ED 2nd. Lansoprazole for maintenance of remission of erosive oesophagitis. Drugs 2002; 62(8):1173-84.
55. Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Porro GB; The Italian Rabeprazole Study Group. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig Liver Dis 2005; 37(10):741-50.
56. Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J Gastroenterol 2005; 11(20):3091-8.
57. Morozov SV, Tsodikova OM, Isakov VA, Tereshchenko SG, Gushchin AE, Shipulin GA. Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump. Ter Arkh; 77(2):21-5.
58. Mulder CJ, Westerveld BD, Smit JM, Oudkerk Pool M, Otten MH, Tan TG, Van Milligen de Wit AW, De Groot GH. Dutch omeprazole MUPS study group. A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. Eur J Gastroenterol Hepatol 2002; 14(6):649-56.
59. Bardhan KD, Van Rensburg C. Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. Aliment Pharmacol Ther 2001; 15(10):1585-91.
60. Frazzoni M, De Micheli E, Grisendi A, Savarino V. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther 2003; 17(2):235-41.
61. Jaspersen D, Diehl KL, Schoeppner H, Geyer P, Martens E. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther 1998; 12(1):49-52.
62. Richter JE, Kahrilas PJ, Johanson J, Maton P, Breiter JR, Hwang C, Marino V, Hamelin B, Levine JG; Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96(3):656-65.
63. Kahrilas PJ, Falk GW, Johnson DA, Schmitt C, Collins DW, Whipple J, D'Amico D, Hamelin B, Joelsson B. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14(10):1249-58.
64. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohss K. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14(7):861-7.
65. Richter JE. Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease. Am J Med 2003; 115 Suppl 3A:179S-187S.
66. Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Naucler E, Eklund S. Expo Study Investigators. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21(6):739-46.
67. Fennerty MB, Johanson JF, Hwang C, Sostek M. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005; 21(4):455-63.
68. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, Skammer W, Levine JG. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97(3):575-83.
69. Rohss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.Eur J Clin Pharmacol 2004; 60(8):531-9. Epub 2004 Sep 2.
70. Chen CY, Lu CL, Luo JC, Chang FY, Lee SD, Lai YL. Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. World J Gastroenterol 2005; 11(20):3112-7.
71. Morozov SV, Tsodikova OM, Isakov VA, Tereshchenko SG, Gushchin AE, Shipulin GA. Esomeprasol and rabeprasol effects on esophageal acidification in patients with gastroesophageal reflux disease, intensively metabolizing inhibitors of proton pump. Ter Arkh 2005; 77(2):21-5.
72. Kaspari S, Kupcinskas L, Heinze H, Berghofer P. Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2005; 17(9):935-41.
73. Dobrilla G, Piazzi L, Fiocca R. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial. Clin Ther 1999; 21(8):1321-32.
74. Witzel L, Gutz H, Huttemann W, Schepp W. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. Aliment Pharmacol Ther 1995; 9(1):19-24.
75. Beker JA, Bianchi Porro G, Bigard MA, Delle Fave G, Devis G, Gouerou H, Maier C. Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 1995; 7(5):407-10.
76. Rehner M, Rohner HG, Schepp W. Comparison of pantoprazole versus omeprazole in the treatment of acute duodenal ulceration--a multicentre study. Aliment Pharmacol Ther 1995; 9(4):411-6.
77. Schepp W, Rehner M, Witzel L. A review of treatment of duodenal and gastric ulcers--pantoprazole vs. omeprazole. Aliment Pharmacol Ther 1994; 8 Suppl 1:53-7.
78. Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer--a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1998; 12(8):789-95.
79. Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdal J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7(5):467-75. Erratum in: Eur J Gastroenterol Hepatol 1996; 8(2):192.
80. Sontag SJ, Kogut DG, Fleischmann R, Campbell DR, Richter J, Robinson M, McFarland M, Sabesin S, Lehman GA, Castell D. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. Am J Gastroenterol 1997; 92(3):429-37.
81. Bardhan KD, Hawkey CJ, Long RG, Morgan AG, Wormsley KG, Moules IK, Brocklebank D. Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research Group. Aliment Pharmacol Ther 1995; 9(2):145-51.
82. Umeda N, Miki K, Hoshino E. Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study. J Clin Gastroenterol 1995; 20 Suppl 1:S17-23.
83. Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23(7):998-1017.
84. Robinson M, Sahba B, Avner D, Jhala N, Greski-Rose PA, Jennings DE. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group. Aliment Pharmacol Ther 1995; 9(1):25-31.
85. Hansen AN, Wahlqvist P, Jorgensen E, Bergheim R, Fagertun H, Lund H, Moum B. Six-month management of patients following treatment for gastroesophageal reflux disease symptoms -- a Norwegian randomized, prospective study comparing the costs and effectiveness of esomeprazole and ranitidine treatment strategies in a general medical practitioners setting. Int J Clin Pract 2005; 59(6):655-64.
86. Arber N, Avni Y, Eliakim R, Swissa A, Melzer E, Rachmilewitz D, Konikoff F. A multicenter, double-blind, randomized controlled study of omeprazole versus ranitidine in the treatment of duodenal ulcer in Israel. Isr J Med Sci 1994; 30(10):757-61.
87. Schepp W, Classen M. Pantoprazole and ranitidine in the treatment of acute duodenal ulcer. A multicentre study. Scand J Gastroenterol 1995; 30(6):511-4.
88. Hotz J, Plein K, Schonekas H, Rose K. Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. Scand J Gastroenterol 1995; 30(2):111-5.
89. Breiter JR, Riff D, Humphries TJ. Rabeprazole is superior to ranitidine in the management of active duodenal ulcer disease: results of a double-blind, randomized North American study. Am J Gastroenterol 2000; 95(4):936-42.
90. Agrawal NM, Campbell DR, Safdi MA, Lukasik NL, Huang B, Haber MM. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers: results of a double-blind, randomized, multicenter study. NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med 2000; 160(10):1455-61.
91. Bardhan KD, Crowe J, Thompson RP, Trewby PN, Keeling PN, Weir D, Crouch SL. Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse. Aliment Pharmacol Ther 1999; 13(6):827-32.
92. Michel P, Duhamel C, Bazin B, Raoul JL, Person B, Bigard MA, Legoux JL, Sallerin V, Colin R. Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study. Gastroenterol Clin Biol 1994; 18(12):1102-5.
93. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15(7):917-26.
94. Shin JM, Cho YM, Sachs G: chemistry of covalent inhibition of the gastric H/K ATPase by proton pump inhibitors. Journal of the American Chemical Society 2004; 126:7800-7811.
95. Kakinoki B, Ono C, Yamazaki N, Chikamatsu N, Wakatsuki D, Uchiyama K, Morinaka Y. General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine. Methods Find Exp Clin Pharmacol 1999; 21(3):179-87.
96. Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol 1999; 51(4):457-64.
97. Uchiyama K, Wakatsuki D, Kakinoki B, Takeuchi Y, Araki T, Morinaka Y. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol 1999; 21(2):115-22.
98. Galmiche JP, Bruley Des Varannes S, Ducrotte P, Sacher-Huvelin S, Vavasseur F, Taccoen A, Fiorentini P, Homerin M. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004; 19(6):655-62.
99. Galmiche JP, Bruley Des Varannes S, Ducrotte P, Sacher-Huvelin S, Vavasseur F, Taccoen A, Fiorentini P, Homerin M. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther 2004; 19(6):655-62.
100. Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, Taccoen A, Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life: Comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005; 100(9):1949-56.
101. Galmiche JP, Sacher-Huvelin S, Bruley des Varannes S, Vavasseur F, Taccoen A, Fiorentini P, Homerin M. A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers. Aliment Pharmacol Ther 2005; 21(5):575-82.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008